News | February 23, 2026
Morepen Labs lands record Rs. 825 crore global CDMO contract
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Morepen Laboratories has reported total income of Rs. 429.64 crores during the period ended June 30, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
AstraZeneca Pharma India discontinues manufacturing of Imdur
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
Morepen Laboratories approves hiving off of medical devices business
Morepen Labs successfully raised Rs. 200 Crore through QIP
Sharma joined the Morepen Lab in 2004
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
